바이오인포매틱스 공동 연구·라이선싱 계약에 대해 조사했으며, 기업이 어떻게, 또 왜 바이오인포매틱스 계약을 시행하는지에 관한 상세한 이해와 분석을 제공하고 있습니다.
목차
개요
제1장 서론
제2장 바이오인포매틱스 계약의 동향
- 서론
- 과거 수년간의 바이오인포매틱스 계약
- 가장 활발한 바이오인포매틱스 계약 기업
- 바이오인포매틱스 계약 : 계약 유형별
- 바이오인포매틱스 계약 : 치료 영역별
- 바이오인포매틱스 계약 : 산업 부문별
- 바이오인포매틱스 계약의 계약 조건
- 바이오인포매틱스 계약 헤드라인 금액
- 바이오인포매틱스 계약 선불
- 바이오인포매틱스 계약 마일스톤 지불
- 바이오인포매틱스 로열티율
제3장 주요 바이오인포매틱스 계약
제4장 가장 활발한 바이오인포매틱스 계약 기업
- 서론
- 가장 활발한 바이오인포매틱스 계약 기업
- 가장 활발한 바이오인포매틱스 계약 기업의 개요
제5장 바이오인포매틱스 계약 디렉토리
제6장 바이오인포매틱스 계약 : 기술 유형별
- 계약 디렉토리
- 계약 디렉토리 - 바이오인포매틱스 계약 : 기업별(A-Z)
- 계약 디렉토리 - 바이오인포매틱스 계약 : 계약 유형별
- 계약 디렉토리 - 바이오인포매틱스 계약 : 치료 영역별
- 계약 유형의 정의
- Biopharma Research Ltd 소개
- Current Partnering
- Current Agreements
- Current Partnering로부터의 최근 리포트 타이틀
KSA
Bioinformatic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the bioinformatic deals entered into by the world's leading biopharma companies.
Fully revised and updated, the report provides details of bioinformatic deals from 2019 to 2024.
The report provides a detailed understanding and analysis of how and why companies enter bioinformatic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 899 bioinformatic deals announced since 2019 including financial terms where available including links to online deal records of actual bioinformatic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of bioinformatic dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in bioinformatic dealmaking since 2019.
Chapter 3 provides an overview of the leading bioinformatic deals since 2019. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in bioinformatic dealmaking with a brief summary followed by a comprehensive listing of bioinformatic deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of bioinformatic deals signed and announced since Jan 2019, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of bioinformatic partnering deals signed and announced since Jan 2019. The chapter is organized by specific bioinformatic technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in bioinformatic deal making since 2019.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Bioinformatic Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse bioinformatic collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
- Bioinformatic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of bioinformatic trends and structure of deals entered into by leading biopharma companies worldwide.
Bioinformatic Collaboration and Licensing Deals includes:
- Trends in bioinformatic dealmaking in the biopharma industry
- Directory of bioinformatic deal records covering pharmaceutical and biotechnology
- The leading bioinformatic deals by value
- Most active bioinformatic licensing dealmakers
- Bioinformatic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in bioinformatic dealmaking
- 2.1. Introduction
- 2.2. Bioinformatic deals over the years
- 2.3. Most active bioinformatic dealmakers
- 2.4. Bioinformatic deals by deal type
- 2.5. Bioinformatic deals by therapy area
- 2.6. Bioinformatic deals by industry sector
- 2.7. Deal terms for bioinformatic deals
- 2.7.1 Bioinformatic deals headline values
- 2.7.2 Bioinformatic deal upfront payments
- 2.7.3 Bioinformatic deal milestone payments
- 2.7.4 Bioinformatic royalty rates
Chapter 3 - Leading bioinformatic deals
- 3.1. Introduction
- 3.2. Top bioinformatic deals by value
Chapter 4 - Most active bioinformatic dealmakers
- 4.1. Introduction
- 4.2. Most active bioinformatic dealmakers
- 4.3. Most active bioinformatic deals company profiles
Chapter 5 - Bioinformatic contracts dealmaking directory
- 5.1. Introduction
- 5.2. Bioinformatic contracts dealmaking directory
Chapter 6 - Bioinformatic dealmaking by technology type
- Deal directory
- Deal directory - Bioinformatic deals by company A-Z
- Deal directory - Bioinformatic deals by deal type
- Deal directory - Bioinformatic deals by therapy area
- Deal type definitions
- About Biopharma Research Ltd
- Current Partnering
- Current Agreements
- Recent report titles from Current Partnering
Table of figures
- Figure 1: Bioinformatic deals since 2019
- Figure 2: Active bioinformatic dealmaking activity - 2019 - 2024
- Figure 3: Bioinformatic deals by deal type since 2019
- Figure 4: Bioinformatic deals by therapy area since 2019
- Figure 5: Bioinformatic deals by industry sector since 2019
- Figure 6: Bioinformatic deals with a headline value
- Figure 7: Bioinformatic deals with an upfront value
- Figure 8: Bioinformatic deals with a milestone value
- Figure 9: Bioinformatic deals with a royalty rate value
- Figure 10: Top bioinformatic deals by value since 2019
- Figure 11: Most active bioinformatic dealmakers 2019 - 2024
- Figure 12: Bioinformatic deals by technology type since 2019
